CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Discussion with Dr. Natasha Kekre, Hematologist and Clinician Scientist.
A Discussion with Dr. Natasha Kekre, Hematologist and Clinician Scientist.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Natasha Kekre医生自2015年起任职于渥太华医院医学部血液科移植与细胞治疗项目。她同时是渥太华医院研究所的科学家,并担任渥太华大学医学副教授。她在温莎大学完成理学学士学位,随后取得渥太华大学医学学位;之后在渥太华大学接受内科和血液科培训,并在波士顿Dana-Farber癌症研究所完成干细胞移植专科培训,同时取得哈佛大学公共卫生硕士学位。她的研究重点是开发早期临床试验,并将本土研发的治疗策略从实验室推进至临床。她与加拿大各地科学家和医生合作,建立加拿大CAR-T 细胞平台。CAR-T 细胞是经过工程化改造、能够杀伤癌细胞的免疫细胞;这一合作旨在让加拿大患者能够接受这项令人振奋的新疗法。
[Figure: see text] Dr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology, within the Transplant and Cellular Therapy Program at The Ottawa Hospital since 2015. She is also a scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor's in Science at the University of Windsor then obtained her medical degree from the University of Ottawa.
She trained at the University of Ottawa in Internal Medicine and Hematology, then did fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston, MA with a Masters in Public Health from Harvard University. Her research is focused on developing early phase clinical trials and moving home grown therapeutic strategies from the lab to patients in the clinic.
She has collaborated with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells), bringing this exciting new therapy to Canadian patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。